This promotional material is intended for UK Healthcare Professionals experienced in the diagnosis and treatment of psoriasis and psoriatic arthritis. SKYRIZI® (risankizumab) and adalimumab prescribing information & adverse event reporting information can be found below.
UK-RISN-230338. Date of preparation May 2024.
The Clear Horizons series provides expert insights and discussion on hot topics in the treatment and clearance of psoriasis.
The series turns to topics as diverse as the presentation of inflammatory skin conditions in skin of colour, provision of optimal care in the post-pandemic era, and what patients really want from their treatment.
The Psoriasis Patient Journey & Optimising Outcomes
Watch an insightful discussion between consultant dermatologists Professor Jonathon Barker and Dr Andrew Pink on aiming to provide optimal care for patients with psoriasis in the post-pandemic era, including how therapy innovation has opened doors for more flexible, patient-centric care.
Biologics in the Real-World Setting (BADBIR)
Discover Dr Kave Shams’ insights on the performance of SKYRIZI in the real-world setting, based on data from the UK BADBIR registry, and how specific attributes of biologic therapies can allow for treatment tailoring to meet the individual needs of patients in your clinical practice.
Skin of Colour
Expert commentary on the importance of understanding how inflammatory skin conditions present in skin of colour, with Dr Laura Savage and Dr Mary Sommerlad.
The Getting Under the Skin with SKYRIZI series illustrates, through diverse case studies, psoriasis patient experiences and provides clarity on how therapy can be tailored to their specific treatment goals and lifestyle needs. Watch to discover the real-life impact of SKYRIZI on patients’ lives.
The York Experience
Dr Keith Wu and Pauline Stopford- Taylor revisit their experience setting up a specialist service in York. They also illustrate the convenience in dosing and impact of SKYRIZI by sharing their treatment journey with a patient whose psoriasis of the hands was affecting his ability to act as a primary carer for his wife.
Dressed for Winter in Summer
After severe psoriasis impacted her choice of clothing, relationships, and mood for many years, a 34-year-old female patient experiences skin clearance with SKYRIZI.
Hear from leading experts who provide their take on SKYRIZI’s efficacy data, real-world use, dosing regimen, safety profile, and associated healthcare resources.
Counting the cost -
A healthcare resource utilisation case study in PSO
Dr Emma McMullen shares her thoughts on how the dermatology service adapted post-pandemic, and how AbbVie’s Cost to Clear tool drove service improvement at Salford.
Dermatology in Practice: Real-world insights (long term data)
In it for the long run – Dr Melinda Gooderham and Dr Laura Savage draw insights from patient case studies as well as the long-term clinical and real-world biologic persistence data for SKYRIZI to discuss changes in the treatment landscape for patients with psoriasis.
Dermatology in Practice: Real-world insights (IL-23 inhibitors)
If you don’t succeed, try again – using real-world case studies and drawing on data from the aIMM study, Dr Melinda Gooderham and Dr Laura Savage discuss the potential benefits of IL-23 inhibitors for IL-17-failure patients with psoriasis.
Get to grips with the basics behind SKYRIZI with fundamental educational content on the therapy.
References
- Reich K, et al. Lancet 2019; 394: 576-586.
- Gordon KB, et al. Lancet 2018; 392: 650-661.
- Warren RB, et al. Risankizumab vs Secukinumab in Patients with Moderate-to-Severe Plaque Psoriasis: A Phase 3 Trial, Presented at AAD 2020.
- SKYRIZI: Summary of Product Characteristics.
UK-RISN-240157. Date of preparation: June 2024.
